Name: TL13-112
Brand: BOC Sciences
Price: 299 USD
Availability: MadeToOrder

Size

Price

Stock

Quantity

5 mg

$299

In stock

Purity

≥98%

Solubility

Soluble in DMSO

Appearance

Yellow Solid

Storage

Store at -20°C

Shipping

Room temperature in continental US; may vary elsewhere.

IUPACName

N-[2-[2-[2-[4-[4-[[5-chloro-4-(2-propan-2-ylsulfonylanilino)pyrimidin-2-yl]amino]-2-methyl-5-propan-2-yloxyphenyl]piperidin-1-yl]ethoxy]ethoxy]ethyl]-2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetamide

Synonyms

TL 13-112; TL-13-112; N-[2-[2-[2-[4-[4-[[5-Chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]-1-piperidinyl]ethoxy]ethoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]acetamide; N-(2-{2-[2-(4-{4-[(5-Chloro-4-{[2-(isopropylsulfonyl)phenyl]amino}-2-pyrimidinyl)amino]-5-isopropoxy-2-methylphenyl}-1-piperidinyl)ethoxy]ethoxy}ethyl)-N2-[2-(2,6-dioxo-3-piperidinyl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]glycinamide; Acetamide, N-[2-[2-[2-[4-[4-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-methyl-5-(1-methylethoxy)phenyl]-1-piperidinyl]ethoxy]ethoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-

Density

1.350±0.06 g/cm3 (Predicted)

InChI Key

XIRQUXILNXIWDI-UHFFFAOYSA-N

InChI

InChI=1S/C49H60ClN9O10S/c1-29(2)69-40-26-34(31(5)25-38(40)55-49-53-27-35(50)45(57-49)54-36-10-6-7-12-41(36)70(65,66)30(3)4)32-15-18-58(19-16-32)20-22-68-24-23-67-21-17-51-43(61)28-52-37-11-8-9-33-44(37)48(64)59(47(33)63)39-13-14-42(60)56-46(39)62/h6-12,25-27,29-30,32,39,52H,13-24,28H2,1-5H3,(H,51,61)(H,56,60,62)(H2,53,54,55,57)

SMILES

CC(OC1=CC(C2CCN(CC2)CCOCCOCCNC(CNC3=CC=CC4=C3C(N(C4=O)C5CCC(NC5=O)=O)=O)=O)=C(C=C1NC6=NC=C(C(NC7=CC=CC=C7S(=O)(C(C)C)=O)=N6)Cl)C)C

Mechanism

Target: TL13-112 selectively targets anaplastic lymphoma kinase, including oncogenic ALK fusion proteins.

Binding site: Its ceritinib-derived ligand binds the ATP pocket of ALK kinase domain.

Mechanism of action: TL13-112 is a cereblon-recruiting ALK PROTAC generated by conjugating a ceritinib-derived ALK ligand to a pomalidomide-based CRBN ligand. This bifunctional architecture promotes induced proximity between ALK and CRL4CRBN ubiquitination machinery, resulting in ALK ubiquitination and proteasome-dependent degradation. Because ALK fusion proteins drive kinase-dependent signaling and scaffold-associated complexes, TL13-112 enables studies that distinguish enzymatic inhibition from target protein removal. It is useful for evaluating ALK degradation potency, downstream signaling suppression, fusion kinase dependency, and off-target kinase degradation patterns in ALK-driven cellular systems.

Applications

• PROTAC-Mediated Kinase Degradation: TL13-112 is designed to facilitate the targeted degradation of specific kinases, offering researchers a powerful tool to dissect kinase signaling pathways. This application enables the study of kinase function and regulation by selectively degrading these proteins, providing insights into their roles in cellular processes.

• Targeted Oncoprotein Degradation: Utilizing TL13-112 allows for the selective degradation of oncoproteins, aiding in cancer research by elucidating the mechanisms of oncogenesis. By removing these critical proteins, researchers can investigate their contribution to tumorigenesis and explore potential therapeutic targets.

• Protein Homeostasis Studies via PROTAC: TL13-112 serves as an essential reagent for studying protein homeostasis by enabling the targeted degradation of proteins involved in cellular maintenance. This application supports research into the dynamic balance of protein synthesis and degradation, crucial for understanding cellular health and disease states.

• PROTAC-Driven Drug Resistance Analysis: With TL13-112, researchers can explore mechanisms of drug resistance by degrading proteins implicated in resistance pathways. This application provides a unique approach to understanding how cells adapt to therapeutic interventions, offering potential strategies to overcome resistance in various diseases.

1. Chemically induced degradation of anaplastic lymphoma kinase (ALK).

Powell, C.E., Gao, Y., Tan, L., Donovan, K.A., Nowak, R.P., Loehr, A., Bahcall, M., Fischer, E.S., Jänne, P.A., George, R.E. and Gray, N.S., 2018. Journal of medicinal chemistry, 61(9), pp.4249-4255.

We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines. These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide. We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1. In addition, proteomic profiling demonstrated that these compounds also promote the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).

ConcentrationVolumeMass	1 mg	5 mg	10 mg
0.5 mM	1.99 mL	9.97 mL	19.95 mL
2.5 mM	0.4 mL	1.99 mL	3.99 mL
5 mM	0.2 mL	1 mL	1.99 mL
25 mM	0.04 mL	0.2 mL	0.4 mL

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂